The vision of the FY11 Duchenne Muscular Dystrophy Research Program (DMDRP) is to extend and improve the function, quality of life, and life span for all individuals diagnosed with DMD. As such, the DMDRP is seeking to fund research to accelerate the development and clinical testing of new therapeutics and increase our understanding of successes and failures of therapeutics in clinical trials. The DMDRP Investigator-Initiated Research Award (IIRA) mechanism supports studies that will make an important contribution toward understanding mechanisms of initiation or progression, and/or improving patient care for DMD. Research projects should focus on translational research that will accelerate the movement of promising ideas in DMD into clinical applications.
